Search clinical trials for: Candesartan Cilexetil 8mg

Total 12107 results

HK inno.N Corporation

Unknown

Pharmacokinetic Interactions of Candesartan Cilexetil and Amlodipine Besylate (CCA)

Healthy
AstraZeneca

Completed

Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo

Hypertension

Russian Federation, Latvia, Romania, Slovakia, Belgium, Malta
The Japanese Society of Hypertension

Unknown

Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients

Cardiovascular Diseases | Hypertension

Japan
Shin Poong Pharmaceutical Co. Ltd.

Completed

Safety and Pharmacokinetics Study of Amlodipine 10mg and Candesartan 32mg

Healthy

Korea, Republic of
PD Dr. Grégoire Wuerzner
Swiss National Science Foundation

Completed

Renal Response to Lower Body Negative Pressure in Pre-hypertensive States

Hypertension | Obesity | White Coat Hypertension | Resistant Hypertension

Switzerland
University of Aarhus

Completed

The Absorption of Vitamin B12 Among Healthy Pregnant Women

Pregnancy

Denmark
Bayer

Completed

Single Dose Escalation Study to Investigate the Pharmacokinetics as Well as Safety and Tolerability of a Concomitant Administration of Nifedipne GITS and Candesartan Tablets Under Fasting Conditions in Healthy Male Subjects in an Open Label, Non-randomized, Sequential Design.

Clinical Pharmacology

Germany
Bayer

Completed

Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension

Hypertension

Germany, United States, Canada, Poland, United Kingdom, Belgium
Kyorin University
Ministry of Health, Labour and Welfare, Japan

Unknown

CCB Safety Study in Treatment of Hypertension of ADPKD

Kidney, Polycystic, Autosomal Dominant

Japan
Augusta University
National Heart, Lung, and Blood Institute (NHLBI)

Active, not recruiting

Adiposity and Endothelin Receptor Function (END-RF)

Hypertension

United States
Washington University School of Medicine
University of Sydney; ACCESS Community Health Network

Active, not recruiting

Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension (QUARTET USA)

Hypertension

United States
Takeda

Completed

Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension

Essential Hypertension
Hospital Israelita Albert Einstein
Libbs Farmacêutica LTDA

Recruiting

Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension (OPTION TREAT)

Hypertension

Brazil
AstraZeneca
Iqvia Pty Ltd

Completed

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults (STORM CHASER)

COVID-19

United States, United Kingdom
Institut für Pharmakologie und Präventive Medizin

Completed

Sevicontrol-1: Efficacy and Safety of a Fixed Combination of Olmesartan/ Amlodipine (Sevicontrol1)

Hypertension

Germany
AstraZeneca

Completed

TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial

Hypertension

United States
Chong Kun Dang Pharmaceutical

Completed

To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure (CANTABILE)

Hypertension | Congestive Heart Failure

Korea, Republic of
University of California, San Francisco
United States Department of Defense

Not yet recruiting

Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury (APT-TBI-01)

Traumatic Brain Injury

United States
Bayer

Completed

Pivotal Bioequivalence FDC Nifedipine / Candesartan vs. Loose Combination of Single Components, Fed

Hypertension, Essential

Germany
Chong Kun Dang Pharmaceutical

Completed

CKD-330 Drug-Drug Interaction Study (Candesartan) (CKD-330(C))

Hypertension

Korea, Republic of
AstraZeneca

Completed

Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg

Hypertension

United Kingdom, Germany, Sweden, Estonia, Lithuania, Poland, Ukraine, Denmark, Netherlands, France, Former Serbia and Montenegro
EMS

Withdrawn

Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control

Essential Arterial Hypertension
HanAll BioPharma Co., Ltd.

Unknown

Bioequivalence Study (Candesartan 16 mg and Amlodipine 10 mg)

Hypertension
Takeda

Completed

Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese Patients With Hypertension.

Hypertension | Obesity

Germany
Ahn-Gook Pharmaceuticals Co.,Ltd

Unknown

Investigate a Interaction of Candesartan and Atorvastatin in Healthy Male Sugjects

Healthy Male Subjects

Korea, Republic of
Alvogen Korea

Completed

DP-R208 Pharmacokinetic Study

Healthy
Alvogen Korea

Completed

Clinical Trial to Compare the Pharmacokinetics of DP-R208

Healthy
Bayer

Completed

Single Dose Bioequivalence Study Comparing Nifedipine/Candesartan FDC (Fixed Dose Combination) With Loose Combination of Nifedipine GITS (Gastro-intestinal Therapeutic System) Plus Candesartan and Single Components Under Fasting Conditions

Hypertension, Essential

Germany
Institut de Recherches Cliniques de Montreal
Ottawa Hospital Research Institute

Completed

Pharmacodynamic Influences of Candesartan, Atenolol, Hydrochlorothiazide and Drug Combinations in Hypertensive Patients.

Hypertension

Canada
Third Military Medical University

Completed

A Randomized, Double-Blind, Active Control Trial Comparing Effects of Telmisartan, Candesartan and Amlodipine, Alone or Plus Metformin, on Non-Diabetic, Obese Hypertensive Patients (HOT-ACME)

Hypertension | Obesity

China
GlaxoSmithKline

Completed

A Study in Asthmatics to Determine the Efficacy and Dose Response of Repeat Doses of GW870086X on Forced Expiratory Volume in 1 Second (FEV1)

Asthma

Germany, South Africa, Bulgaria
Biomedis International Ltd.

Unknown

Recurrent Stroke Prevention Clinical Outcome Study (RESPECTS)

Stroke | Hypertension | Blood Pressure

Japan
J2H Biotech

Completed

Phase 1 Study to Investigate Safety, Tolerability, PK/PK of J2H-1702 in Healthy Males

Non-alcoholic Steatohepatitis

Korea, Republic of
Takeda

Withdrawn

An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine in Participants With Mild/Moderate Essential Hypertension

Hypertension

China
An-Najah National University

Recruiting

Continuing or Discontinuing ACE/ARBs in Patients With Chronic Kidney Disease Undergoing Coronary Angiography

Chronic Kidney Diseases | Ischemic Heart Disease | Contrast-induced Nephropathy

Palestinian Territory, occupied
Göteborg University
Sahlgrenska University Hospital, Sweden

Completed

Expression and Function of the Renin-Angiotensin System in the Esophagus

Barrett's Esophagus

Sweden
AstraZeneca

Completed

Candesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP)

Hypertension | Left Ventricular Hypertrophy

Korea, Republic of
University of California, San Diego
Baxter Healthcare Corporation; Scripps Health; Home Dialysis Therapies of San...

Active, not recruiting

Directed Use of REmote Patient Management System AMia to Achieve Prescribed Dry Weight (DREAM-APD)

Efficacy | Safety Issues

United States
Alvogen Korea

Completed

Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy

Hypertension | Cholesterolemia

Korea, Republic of
Helixmith Co., Ltd.

Completed

Safety Study of Gene Therapy in Treating Lower Leg Ischemia

Critical Limb Ischemia

United States
Chong Kun Dang Pharmaceutical

Completed

Study to Compare the Safety and Pharmacokinetics of CKD-330 8/5mg With Coadministration of the Two Separate Drugs

Hypertension

Korea, Republic of
Xijing Hospital

Withdrawn

China Stroke Secondary Prevention Trial (CSSPT)

Stroke | Transient Ischemic Attack

China
University of Alabama at Birmingham
National Heart, Lung, and Blood Institute (NHLBI); AstraZeneca

Completed

Impact of Diabetes on Left Ventricular Remodeling (P3)

Diabetes

United States
Chong Kun Dang Pharmaceutical

Completed

Bioequivalence Study (Candesartan 8 mg and Amlodipine 5 mg)

Hypertension

Korea, Republic of
Baim Institute for Clinical Research
Beth Israel Deaconess Medical Center

Completed

Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions (CORAL)

Cardiovascular Diseases | Atherosclerosis | Renal Artery Obstruction | Hypertension, Renovascular

United States
Montreal Heart Institute
AstraZeneca

Completed

A Pharmacogenomic Study of Candesartan in Heart Failure

Heart Failure

Canada
Institut für Pharmakologie und Präventive Medizin

Completed

Efficacy and Safety of a Therapy Change From Candesartan 32 mg to Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg (Sevicontrol-2)

Hypertension

Germany
Western Regional Medical Center

Terminated

Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer (PembroMab)

Breast Cancer | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Advanced Cancer

United States
St George's, University of London

Terminated

The Renin-Angiotensin System in Essential Hypertension

Hypertension

United Kingdom
AstraZeneca
Takeda

Completed

DIabetic Retinopathy Candesartan Trials (DIRECT)

Type 2 Diabetes

3

Subscribe